{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:33:41Z","timestamp":1791920021290,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clnesp.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:40:27Z","timestamp":1644878427000},"page":"267-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis"],"prefix":"10.1016","volume":"48","author":[{"given":"Tomonori","family":"Kobayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clnesp.2022.02.002_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.21037\/atm-21-3098","article-title":"Identifying a possible new target for diagnosis and treatment of postmenopausal osteoporosis through bioinformatics and clinical sample analysis","volume":"9","author":"Liu","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clnesp.2022.02.002_bib2","series-title":"Seminars in cell & developmental biology","article-title":"Interaction between bone and immune cells: implications for postmenopausal osteoporosis","author":"Fischer","year":"2021"},{"issue":"21","key":"10.1016\/j.clnesp.2022.02.002_bib3","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00018-013-1317-1","article-title":"The role of estrogen receptor alpha in the regulation of bone and growth plate cartilage","volume":"70","author":"Borjesson","year":"2013","journal-title":"Cell Mol Life Sci : CMLS"},{"issue":"5","key":"10.1016\/j.clnesp.2022.02.002_bib4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J\u00a0Bone Miner Res : the official journal of the American Society for Bone and Mineral Research"},{"issue":"12","key":"10.1016\/j.clnesp.2022.02.002_bib5","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J\u00a0Bone Miner Res : the official journal of the American Society for Bone and Mineral Research"},{"issue":"16","key":"10.1016\/j.clnesp.2022.02.002_bib6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.clnesp.2022.02.002_bib7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.clnesp.2022.02.002_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clnesp.2022.02.002_bib9","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone reports"},{"issue":"1","key":"10.1016\/j.clnesp.2022.02.002_bib10","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2022.02.002_bib11","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.clnesp.2022.02.002_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jbmr.555","article-title":"Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone","volume":"27","author":"Harada","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5484","key":"10.1016\/j.clnesp.2022.02.002_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.clnesp.2022.02.002_bib14","series-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","first-page":"1","volume":"vol. 843","year":"1994"},{"issue":"3","key":"10.1016\/j.clnesp.2022.02.002_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"9","key":"10.1016\/j.clnesp.2022.02.002_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clnesp.2022.02.002_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"Shiraki","year":"2011","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"3","key":"10.1016\/j.clnesp.2022.02.002_bib18","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1210\/jc.2004-0826","article-title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures","volume":"90","author":"Gallagher","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnesp.2022.02.002_bib19","doi-asserted-by":"crossref","first-page":"17021","DOI":"10.1038\/boneres.2017.21","article-title":"Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone research"},{"issue":"3","key":"10.1016\/j.clnesp.2022.02.002_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clnesp.2022.02.002_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00198-012-2006-x","article-title":"Differences in regional bone metabolism at the spine and hip: a quantitative study using (18)F-fluoride positron emission tomography","volume":"24","author":"Puri","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.clnesp.2022.02.002_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.clnesp.2022.02.002_bib23","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.clnesp.2022.02.002_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1373\/clinchem.2018.300905","article-title":"Albumin-adjusted calcium and ionized calcium","volume":"65","author":"Payne","year":"2019","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.clnesp.2022.02.002_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bone.2011.05.022","article-title":"Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats","volume":"49","author":"de Freitas","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.clnesp.2022.02.002_bib26","first-page":"174","article-title":"Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs","volume":"7","author":"Schacht","year":"2007","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"issue":"1","key":"10.1016\/j.clnesp.2022.02.002_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13018-020-01896-z","article-title":"The therapeutic effect to eldecalcitol\u00a0+ bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis","volume":"15","author":"Zheng","year":"2020","journal-title":"J\u00a0Orthop Surg Res"},{"issue":"5","key":"10.1016\/j.clnesp.2022.02.002_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00774-016-0792-5","article-title":"Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis","volume":"35","author":"Ebina","year":"2017","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"1","key":"10.1016\/j.clnesp.2022.02.002_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jos.2020.11.009","article-title":"Effects of eldecalcitol alone or a bone resorption inhibitor with eldecalcitol on bone mineral density, muscle mass, and exercise capacity for postmenopausal women with distal radius fractures","volume":"27","author":"Maeda","year":"2020","journal-title":"J\u00a0Orthop Sci\u202f: official journal of the Japanese Orthopaedic Association"},{"key":"10.1016\/j.clnesp.2022.02.002_bib30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.clnesp.2022.02.002_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.clnesp.2022.02.002_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnesp.2022.02.002_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2018.03.001","article-title":"Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody","volume":"8","author":"Boyce","year":"2018","journal-title":"Bone reports"},{"issue":"6","key":"10.1016\/j.clnesp.2022.02.002_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00198-017-3967-6","article-title":"Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study","volume":"28","author":"Tamaki","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clnesp.2022.02.002_bib35","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457722000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457722000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:05:51Z","timestamp":1762499151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457722000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"alternative-id":["S2405457722000511"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2022.02.002","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}